Table 1.
American College of Radiology classification of gadolinium-based contrast agent risk for nephrogenic systemic fibrosis
| American College of Radiology Group | Gadolinium-Based Contrast Agent | Structure | Binding Affinity Log Ktherm |
| Group 1: Associated with greatest risk of NSF | Gadodiamide (Omniscan) | Linear, nonionic | 16.9 |
| Gadoversetamide (OptiMARK) | Linear, nonionic | 16.6 | |
| Gadopentetate dimeglumine (Magnevist) | Linear, ionic | 22.5 | |
| Group 2: Associated with few, if any, cases of unconfounded NSF | Gadobenate dimeglumine (Multihance) | Linear, ionic | 22.6 |
| Gadobutrol (Gadavist) | Macrocyclic, nonionic | 21.8 | |
| Gadoteridol (Prohance) | Macrocyclic, nonionic | 23.8 | |
| Gadoteric acid (Dotarem) | Macrocyclic, ionic | 24.7 | |
| Group 3: Limited data regarding NSF risk | Gadoexetate disodium (Eovist) | Linear, ionic | 22.6 |
NSF, nephrogenic systemic fibrosis.